Â鶹´«Ã½É«ÇéƬ

News

A common parasite could one day deliver drugs to the brain

Bill Sullivan
Sept. 29, 2024

Parasites on human and veterinary health. But researchers may have found a way for patients with brain disorders and a common brain parasite to become frenemies.

A new study published in has pioneered the use of a single-celled parasite, Toxoplasma gondii, to inject therapeutic proteins into brain cells. The about what it lets in, including many drugs, which limits treatment options for neurological conditions.

As a , I’ve dedicated my career to finding ways to kill dangerous parasites such as Toxoplasma. I’m fascinated by the prospect that we may be able to use their weaponry to instead treat other maladies.

Microbes as medicine

Ever since scientists realized that microscopic organisms can cause illness – what’s called the 19th-century – humanity has been on a quest to keep infectious agents out of our bodies. Many people’s understandable aversion to germs may make the idea of adapting these microbial adversaries for therapeutic purposes seem counterintuitive.

But preventing and treating disease by co-opting the very microbes that threaten us has a history that long predates germ theory. , people in the Middle East and Asia noted that those lucky enough to survive smallpox never got infected again. These observations led to the practice of purposefully exposing an uninfected person to the material from an infected person’s pus-filled sores – which unbeknownst to them contained weakened smallpox virus – to protect them from severe disease.

The concept of inoculation developed with smallpox outbreaks several centuries ago.
,
The concept of inoculation developed with smallpox outbreaks several centuries ago.

This that have saved countless lives.

Viruses, bacteria and parasites have also evolved many tricks to penetrate organs such as the brain and could be into the body. Such uses could include and known as .

Why can’t we just take a pill for brain diseases?

Pills offer a convenient and effective way to get medicine into the body. such as aspirin or penicillin are small and easily absorbed from the gut into the bloodstream.

such as insulin or semaglutide, on the other hand, are large and complex molecules that are vulnerable to breaking down in the stomach before they can be absorbed. They are also too big to pass through the intestinal wall into the bloodstream.

All drugs, especially biologics, have great difficulty penetrating the brain due to the . The blood-brain barrier is a layer of cells lining the brain’s blood vessels that acts like a gatekeeper to block germs and other unwanted substances from gaining access to neurons.

Toxoplasma offers delivery service to brain cells

Toxoplasma parasites . Infection can occur in multiple ways, including ingesting spores released in the stool of infected cats or consuming contaminated meat or water. in otherwise healthy people produces only mild symptoms but can be serious in immunocompromised people and to .

Unlike most pathogens, Toxoplasma can cross the blood-brain barrier and invade brain cells. Once inside neurons, the parasite releases a suite of proteins that , which may be a factor in the it causes in infected animals and people.

Scientists retooled Toxoplasma to deliver drugs to neurons.

In a new study, a global team of researchers to secrete proteins into its host cell. The team genetically engineered Toxoplasma to make a hybrid protein, fusing one of its secreted proteins to a , which regulates gene activity in the brain – in effect, giving the MeCP2 a piggyback ride into neurons. Researchers found that the parasites secreted the MeCP2 protein hybrid into neurons grown in a petri dish as well as in the brains of infected mice.

A genetic deficiency in MECP2 causes a rare brain development disorder called . Gene therapy trials to treat Rett syndrome are underway. If Toxoplasma can deliver a form of MeCP2 protein into brain cells, it may provide another option to treat this currently incurable condition. It also may offer another treatment option for other neurological problems that arise from errant proteins, and .

The long road ahead

The is long and filled with obstacles, so don’t expect to see engineered Toxoplasma in the clinic anytime soon.

The obvious complication in using Toxoplasma for medical purposes is that it can produce a serious, lifelong infection that is currently incurable. Infecting someone with Toxoplasma can , including the brain, eyes and heart.

The task scientists face is to modify Toxoplasma to safely penetrate the brain.
Ke Hu and John M. Murray/Wikimedia Commons
The task scientists face is to modify Toxoplasma to safely penetrate the brain.

However, up to currently carry Toxoplasma in their brain, apparently without incident. Emerging studies have correlated infection with increased risk of schizophrenia, rage disorder and recklessness, hinting that this quiet infection may be .

The widespread prevalence of Toxoplasma infections may also be another complication, as it disqualifies many people from using it for treatment. Since the billions of people who already carry the parasite have developed immunity against future infection, therapeutic forms of Toxoplasma would be rapidly destroyed by their immune systems once injected.

In some cases, the benefits of using Toxoplasma as a drug delivery system may outweigh the risks. Engineering benign forms of this parasite could produce the proteins patients need without harming the organ – the brain – that defines who we are.

This article is republished from under a Creative Commons license. Read the .

The Conversation

Enjoy reading ASBMB Today?

Become a member to receive the print edition four times a year and the digital edition weekly.

Learn more
Bill Sullivan

Bill Sullivan is a professor at Indiana University School of Medicine and the author of several books.

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Science

Science highlights or most popular articles

Elucidating how chemotherapy induces neurotoxicity
Award

Elucidating how chemotherapy induces neurotoxicity

Dec. 2, 2024

Andre Nussenzweig will receive the Bert and Natalie Vallee Award at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.

Where do we search for the fundamental stuff of life?
Essay

Where do we search for the fundamental stuff of life?

Dec. 1, 2024

Recent books by Thomas Cech and Sara Imari Walker offer two perspectives on where to look for the basic properties that define living things.

UCLA researchers engineer experimental drug for preventing heart failure after heart attacks
News

UCLA researchers engineer experimental drug for preventing heart failure after heart attacks

Nov. 30, 2024

This new single-dose therapy blocks a protein that increases inflammation and shows promise in enhancing muscle repair in preclinical models.

The decision to eat may come down to these three neurons
News

The decision to eat may come down to these three neurons

Nov. 28, 2024

The circuit that connects a hunger-signaling hormone to the jaw to stimulate chewing movements is surprisingly simple, Rockefeller University researchers have found.

Curiosity turned a dietitian into a lipid scientist
Award

Curiosity turned a dietitian into a lipid scientist

Nov. 27, 2024

Judy Storch will receive the Avanti Award in Lipids at the 2025 ASBMB Annual Meeting, April 12–15 in Chicago.

From receptor research to cancer drug development: The impact of RTKs
Award

From receptor research to cancer drug development: The impact of RTKs

Nov. 26, 2024

Joseph Schlessinger will receive the ASBMB Herbert Tabor Research Award at the 2025 ASBMB Annual meeting, April 12–15 in Chicago.